Explore the words cloud of the COMBACTE-CDI project. It provides you a very rough idea of what is the project "COMBACTE-CDI" about.
The following table provides information about the project.
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
|Coordinator Country||Netherlands [NL]|
|Total cost||4˙179˙307 €|
|EC max contribution||2˙312˙305 € (55%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2017-11-01 to 2020-10-31|
Take a look of project's partnership.
|1||UNIVERSITAIR MEDISCH CENTRUM UTRECHT||NL (UTRECHT)||coordinator||350˙255.00|
|2||UNIVERSITY OF LEEDS||UK (LEEDS)||participant||1˙330˙476.00|
|3||KLINIKUM DER UNIVERSITAET ZU KOELN||DE (KOELN)||participant||151˙848.00|
|4||ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO||IT (ROMA)||participant||150˙260.00|
|5||ACADEMISCH ZIEKENHUIS LEIDEN||NL (LEIDEN)||participant||137˙676.00|
|6||NACIONALNI LABORATORIJ ZA ZDRAVJE, OKOLJE IN HRANO||SI (MARIBOR)||participant||90˙557.00|
|7||UNIVERSITEIT ANTWERPEN||BE (ANTWERPEN)||participant||58˙556.00|
|8||EBERHARD KARLS UNIVERSITAET TUEBINGEN||DE (TUEBINGEN)||participant||42˙676.00|
|9||ASTRAZENECA AB||SE (SODERTAELJE)||participant||0.00|
|10||BIOMERIEUX SA||FR (Marcy l'Etoile)||participant||0.00|
|11||DA VOLTERRA SAS||FR (PARIS)||participant||0.00|
|12||GLAXOSMITHKLINE BIOLOGICALS SA||BE (RIXENSART)||participant||0.00|
|13||PFIZER LIMITED||UK (SANDWICH)||participant||0.00|
|14||SANOFI PASTEUR SA||FR (LYON)||participant||0.00|
Clostridium difficile infection (CDI) is one of the most prevalent healthcare associated infections, affecting both hospitalized patients and individuals in the community; notably, there is an increasing realization that cases also occur in subjects not recently exposed to healthcare interventions, including antibiotics. CDI poses an extensive burden of morbidity, mortality and healthcare resource utilization, and so requires effective prevention and management strategies. Epidemiological data are, however, limited and studies typically have examined only part of a healthcare economy and usually have been focused on single countries/healthcare systems. Thus, there is a lack of robust, comprehensive data on the impact of CDI across countries in Europe. Furthermore, we know that large variations in the frequency of testing and the sensitivity of CDI diagnostics across European countries mean that the size of the problem is underestimated.
Combating Bacterial Resistance in Europe-CDI (COMBACTE-CDI) therefore aims to develop a detailed understanding of the epidemiology and clinical impact of CDI across multiple European countries. Our project proposal provides a collaborative approach comprising three scientific work packages (WPs). A large epidemiology study will be undertaken across Europe in WP1 to quantify the burden of CDI (incidence, distribution, recurrence, morbidity, mortality, transmission) across the whole healthcare economy. This will be followed by a case/control study in WP2, which along with data collected in a questionnaire will enable the consortium to assess current practices in Europe (guidelines, testing, surveillance, treatment, cost) and their potential impacts. WP3 will create a rich, European, research platform that will provide support for future proof-of-concept and clinical studies of new prevention and treatment strategies for CDI. The three interrelated research WPs will be supported by a management work package (WP4).
COMBACTE-CDI will harmonise with many of the IMI2 objectives; specifically, we aim to improve the health of European citizens by providing evidence of the true epidemiology and transmission of CDI. We will also develop ‘best-practice’ models for diagnosis, treatment and surveillance, which should reduce the incidence and impact of CDI (including mortality) across Europe, and will optimize patient management. Notably, in order to deliver these aims costeffectively and to test the resilience of our data, we will actively link and compare our data with other European projects that include CDI as a target condition. This synergistic approach will be all the more feasible as the participants in COMBACTE-CDI are playing key roles in multiple, relevant, parallel European CDI activities.
Our ambitious proposal aims to go beyond the state of the art in 8 aspects: quantification of CDI in the whole healthcare economy; contemporaneous comparison with animal and food isolates with those within human health; identification of potential drivers of strain clustering, providing enhanced information to aid further trial/study design and conduct; use of a novel highly sensitive diagnostic assay for more accurate CDI case definition; provision of both cost-effectiveness and transmission models to enable further evaluation of interventions; and finally, by comparing overall costs in different European healthcare settings, we will, for the first time, allow simulation of the economic impact of novel CDI treatment options, even prior to market authorization.
COMBACTE-CDI is the merger of excellent European expertise on the clinical, diagnostic, and therapeutic issues related to CDI and the expertise and input of 7 EFPIA partners. It brings together experts that partnered in CDI projects (EUCLID, ECDIS-NET), the largest existing (IMI-funded) clinical and laboratory network in Europe (CLIN-Net and LAB-Net) for successfully executing challenging epidemiological and interventional studies related to bacte
|Report on heterogeneity of testing and delivery of dataset||Documents, reports||2020-02-13 13:11:22|
|Report on current treatment pathways||Documents, reports||2020-02-13 13:11:11|
|Report on high risk groups and delivery of dataset||Documents, reports||2020-02-13 13:11:32|
|Report on recurrent CDI, morbidity and mortality and delivery of dataset||Documents, reports||2020-02-13 13:09:19|
|Report on current surveillance practices||Documents, reports||2020-02-13 13:08:54|
|Report on current guidelines for diagnosis, management and control of CDI||Documents, reports||2020-02-13 13:09:23|
|Report on strain distribution and delivery of dataset||Documents, reports||2020-02-13 13:09:02|
|Full ethical approval of final study protocol from all countries||Documents, reports||2020-01-28 14:45:03|
|Adaptation of COMBACTE website to include COMBACTE-CDI||Websites, patent fillings, videos etc.||2020-01-28 14:45:03|
Take a look to the deliverables list in detail: detailed list of COMBACTE-CDI deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COMBACTE-CDI" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "COMBACTE-CDI" are provided by the European Opendata Portal: CORDIS opendata.
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugsRead More
Bringing a prophylactic Ebola vaccine to licensureRead More
NOVEL GRAM-NEGATIVE ANTIBIOTIC NOWRead More